Immunodominant PstSI antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer

BMC Cancer

Volumn 4, Issue , 2004, Pages

  Sänger, Christian ^a   Busche, Andreas ^a   Bentien, Gabriele ^a   Spallek, Ralf ^b   Jonas, Fatima ^b   Böhle, Andreas ^c   Singh, Mahavir ^b   Brandau, Sven ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b LIONEX DIAGNOSTICS AND THERAPEUTICS GMBH   (Germany)

^c HELIOS AGNES KARLL HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BCG VACCINE; CD83 ANTIGEN; CD86 ANTIGEN; CHROMIUM; GAMMA INTERFERON; IMMUNOSTIMULATING AGENT; INTERLEUKIN 12; PHOSPHATE; PHOSPHATE BINDING PROTEIN; PHOSPHATE TRANSPORTER; PHOSPHATE TRANSPORTER S1; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCG VACCINATION; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL ACTIVATION; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KAPLAN MEIER METHOD; LYMPHOCYTE PROLIFERATION; MEDICAL DOCUMENTATION; MONONUCLEAR CELL; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHOSPHATE TRANSPORT; SIDE EFFECT; SPLEEN CELL; SUPERFICIAL CANCER; TREATMENT OUTCOME; ANIMAL; BLADDER TUMOR; C57BL MOUSE; CANCER TRANSPLANTATION; CELL LINE; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTIGENS, BACTERIAL; CELL LINE; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; NEOPLASM TRANSPLANTATION; PHOSPHATE-BINDING PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 13144264115     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-4-86     Document Type: Article

References (35)

1. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JAJ, Sullivan J, Sarosdy MF, .: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 1991, 325:1205-1209.
2. Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, Whitmore WFJ, Oettgen HF: Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995, 13:1404-1408.
3. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ: 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999, 161:1124-1127.
4. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WFJ: Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989, 141:22-29.
5. Cymes M, Fleischmann JD, Smith E: Invasive bladder cancer treated with intravesical BCG. J Urol 1992, 147:273.
6. Lamm DL: Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 1992, 19:565-572.
7. Steg A, Adjiman S, Debre B: BCG therapy in superficial bladder tumours - complications and precautions. Eur Urol 1992, 21 Suppl 2:35-40.
8. Armstrong RW: Complications after intravesical instillation of bacillus Calmette-Guerin: rhabdomyolysis and metastatic infection. J Urol 1991, 145:1264-1266.
9. Zlotta AR, Van Vooren JP, Denis O, Drowart A, Daffe M, Lefevre P, Schandene L, De Cock M, De Bruyn J, Vandenbussche P, Jurion F, Palfliet K, Simon J, Schulman CC, Content J, Huygen K: What are the immunologically active components of bacille Calmette-Guerin in therapy of superficial bladder cancer? Int J Cancer 2000, 87: 44-852.
10. Rohde D, Gastl G, Biesterfeld S, Plante M, Jakse G: Local expression of cytokines in rat bladder carcinoma tissue after intravesical treatment with Nocardia rubra cell wall skeleton and bacille-Calmette-Guerin. Urol Res 1997, 25:19-24.
11. de Boer EC, De Reijke TM, Vos PC, Kurth KH, Schamhart DH: Immunostimulation in the urinary bladder by local application of Nocardia rubra cell-wall skeletons (Rubratin) and bacillus Calmette-Guerin as therapy for superficial bladder cancer: a comparative study. Clin Infect Dis 2000, 31 Suppl 3:S109-S114.
12. Morales A, Chin JL, Ramsey EW: Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol 2001, 166:1633-1637.
13. Vordermeier HM, Coombes AG, Jenkins P, McGee JP, O'Hagan DT, Davis SS, Singh M: Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. Vaccine 1995, 13:1576-1582.
14. Andersen AB, Hansen EB: Structure and mapping of antigenic domains of protein antigen b, a 38,000-molecular-weight protein of Mycobacterium tuberculosis. Infect Immun 1989, 57: 481-2488.
15. Braibant M, Lefevre P, de Wit L, Peirs P, Ooms J, Huygen K, Andersen AB, Content J: A Mycobacterium tuberculosis gene cluster encoding proteins of a phosphate transporter homologous to the Escherichia coli Pst system. Gene 1996, 176:171-176.
16. Espitia C, Mancilla R: Identification, isolation and partial characterization of Mycobacterium tuberculosis glycoprotein antigens. Clin Exp Immunol 1989, 77:378-383.
17. Young DB, Garbe TR: Lipoprotein antigens of Mycobacterium tuberculosis. Res Microbiol 1991, 142:55-65.
18. Ivanyi J: Tuberculosis: Pathogenesis, Protection and Control. Bloom B (ed) ASMp Press: Washington 1994:437.
19. Singh M, Andersen AB, McCarthy JE, Rohde M, Schutte H, Sanders E, Timmis KN: The Mycobacterium tuberculosis 38-kDa antigen: overproduction in Escherichia coli, purification and characterization. Gene 1992, 117:53-60.
20. Gunther JH, Jurczok A, Wulf T, Brandau S, Deinert I, Jocham D, Bohle A: Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 1999, 59:2834-2837.
21. Shinka T, Hirano A, Uekado Y, Ohkawa T: Clinical study of prognostic factors of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin. Br J Urol 1990, 66: 5-39.
22. Saint F, Salomon L, Quintela R, Cicco A, Hoznek A, Abbou CC, Chopin DK: Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin (BCG) immunotherapy exist?. analysis of a quarter century of literature. Eur Urol 2003, 43:351-360.
23. Bilen CY, Inci K, Erkan I, Ozen H: The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin. J Urol 2003, 169:1702-1705.
24. Riemensberger J, Bohle A, Brandau S: IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 2002, 127:20-26.
25. O'Donnell MA, Luo Y, Chen X, Szilvasi A, Hunter SE, Clinton SK: Role of IL-12 in the induction and potentiation of IFNgamma in response to bacillus Calmette-Guerin. J Immunol 1999, 163: 246-4252.
26. Suttmann H, Jacobsen M, Reiss K, Jocham D, Bohle A, Brandau S: Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol 2004, 172:1490-1495.
27. Brandau S, Bohle A, Thanhauser A, Ernst M, Mattern T, Ulmer AJ, Flad HD: In vitro generation of bacillus Calmette-Guerin-activated killer cells. Clin Infect Dis 2000, 31 Suppl 3:S94-S100.
28. Vordermeier HM, Harris DP, Mehrotra PK, Roman E, Elsaghier A, Moreno C, Ivanyi J: M. tuberculosis-complex specific T-cell stimulation and DTH reactions induced with a peptide from the 38-kDa protein. Scand J Immunol 1992, 35:711-718.
29. Venkataprasad N, Coombes AG, Singh M, Rohde M, Wilkinson K, Hudecz F, Davis SS, Vordermeier HM: Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers. Vaccine 1999, 17:1814-1819.
30. Sfondrini L, Rodolfo M, Singh M, Colombo MP, Colnaghi MI, Menard S, Balsari A: Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice. Cancer Res 2000, 60:3777-3781.
31. Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, Wysocka M, Trinchieri G, Murphy KM, O'Garra A: Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995, 154:5071-5079.
32. Shurin MR, Esche C, Peron JM, Lotze MT: Antitumor activities of IL-12 and mechanisms of action. Chem Immunol 1997, 68:153-174.
33. Flesch IE, Hess JH, Huang S, Aguet M, Rothe J, Bluethmann H, Kaufmann SH: Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J Exp Med 1995, 181:1615-1621.
34. Tripp CS, Wolf SF, Unanue ER: Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci U S A 1993, 90:3725-3729.
35. Shurin MR: Dendritic cells presenting tumor antigen. Cancer Immunol Immunother 1996, 43:158-164.